Two Sigma Securities, LLC Can Fite Bio Pharma Ltd. Transaction History

Two Sigma Securities, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.6 - $8.94 $7,446 - $110,954	12,411 Added 85.16%	26,985 $16,000
Q3 2022 Nov 14, 2022	BUY	$0.74 - $7.9 $10,784 - $115,134	14,574 New	14,574 $11,000
Q1 2022 May 16, 2022	SELL	$0.94 - $1.45 $16,740 - $25,823	-17,809 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$0.98 - $2.15 $17,452 - $38,289	17,809 New	17,809 $23,000
Q3 2021 Nov 15, 2021	SELL	$1.65 - $2.34 $16,795 - $23,818	-10,179 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$1.97 - $2.48 $86,431 - $108,807	-43,874 Reduced 81.17%	10,179 $23,000
Q1 2021 May 17, 2021	BUY	$1.8 - $2.92 $97,295 - $157,834	54,053 New	54,053 $134,000
Q3 2020 Nov 16, 2020	SELL	$1.61 - $2.67 $16,112 - $26,721	-10,008 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$1.28 - $2.5 $12,810 - $25,020	10,008 New	10,008 $20,000
Q3 2019 Nov 14, 2019	SELL	$2.06 - $3.3 $26,806 - $42,942	-13,013 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$2.77 - $12.75 $36,046 - $165,915	13,013 New	13,013 $37,000

1.1K

Ticker CANF
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,191,500
Market Cap $54.7M
Description
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinic...

Get notified when there are updates to the investment portfolio of Two Sigma Securities, LLC, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Securities, LLC with notifications on news.